← Leaderboards
Christopher Ehmann
Pennsylvania State Univ Hershey Med Ctr
$100,551
Attributed
$100,551
Total exposure
19
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $37.9K · FY2005–09$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$100,551 · 19
By mechanism
M01$100,551 · 19
Top collaborators
No co-investigators on record.
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Richard S. Legro$15,817,930
- Kevin Finnbar Staveleyo'carroll$5,239,458
- Jill P Smith$5,480,175
- Witold B. Rybka$244,866
- Pankaj Kumar Singh$18,899,559
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesSourceUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseGrantResearch PersonnelFundingInstitutionLymphomaUpper ArmMaintenancePurposeLymphocyteClinical ResearchLymphResponseNumbersRateCyclophosphamide/FludarabineProtocols, TreatmentClinical Trials, Phase IiiStandards Of Weights And MeasuresMalignant NeoplasmsCyclophosphamide
Grant awards (21)
CLINICAL TRIAL: P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YR$7,858
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE$925
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE$917
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YR$3,651
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE$2,839
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE$1,217
M01 · FY2008 · RR · contact PI
P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YRS OF ADJ TAMOXIF$4,719
M01 · FY2007 · RR · contact PI
PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL$2,178
M01 · FY2007 · RR · contact PI
PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL$1,815
M01 · FY2007 · RR · contact PI
PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL$5,592
M01 · FY2006 · RR · contact PI
PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL$3,871
M01 · FY2006 · RR · contact PI
P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YRS OF ADJ TAMOXIF$3,871
M01 · FY2006 · RR · contact PI
PHASE II: DOXIL CYCLOPHOSPHAMIDE,VINCRISTINE & PREDNISONE:AIDS SYSTEMIC LYMPHOMA$2,858
M01 · FY2006 · RR · contact PI
PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL$11,557
M01 · FY2005 · RR
P3 RAN DB -LETROZOLE VS PLAC PRIMARY BR CA COMPLETING 5 OR 5+ YRS OF ADJ TAMOXIF$11,218
M01 · FY2005 · RR
PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL$7,819
M01 · FY2005 · RR
PHASE 2/3 PACLITAXEL PLUS CARBOPLATIN W/WO BEVACIZUMAB IN NSCLC (ECOG E4599)$4,419
M01 · FY2005 · RR
PHASE II: DOXIL CYCLOPHOSPHAMIDE,VINCRISTINE &PREDNISONE:AIDS SYSTEMIC LYMPHOMA$2,866
M01 · FY2005 · RR
Phase 3 Study:Low Grade Lymph Comp Cyclophosphamide/Fludarabine to Std Ther fol$12,507
M01 · FY2004 · RR
Phase 3 Study:Low Grade Lymph Comp Cyclophosphamide/Fludarabine to Std Ther fol$6,981
M01 · FY2004 · RR
Phase II--Doxil CVP in AIDS Systemic lymphoma$873
M01 · FY2004 · RR